Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 1 of 241 for:    "Thalassemia"
Previous Study | Return to List | Next Study

Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)

This study has been completed.
Sponsor:
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI)
Thalassemia Clinical Research Network
Information provided by:
New England Research Institutes
ClinicalTrials.gov Identifier:
NCT00000623
First received: October 27, 1999
Last updated: March 3, 2014
Last verified: July 2006
  Purpose
The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.

Condition Intervention
Anemia, Cooley's
Beta-Thalassemia
Hematologic Diseases
Thalassemia
Osteoporosis
Iron Overload
Hypertension, Pulmonary
Drug: Deferoxamine
Drug: Deferiprone
Drug: Arginine
Drug: Sildenafil
Drug: Decitabine

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Thalassemia Clinical Research Network (TCRN)

Resource links provided by NLM:


Further study details as provided by New England Research Institutes:

Primary Outcome Measures:
  • Vary by protocol

Estimated Enrollment: 1000
Study Start Date: July 2000
Study Completion Date: July 2006
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   1 Year to 75 Years   (Child, Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
Please refer to specific studies for eligibility criteria.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000623

Locations
United States, California
Children's Hospital Oakland
Oakland, California, United States, 94609
United States, Massachusetts
Children's Hospital
Boston, Massachusetts, United States, 02115
United States, New York
Weill Medical College of Cornell University
New York, New York, United States, 10021
United States, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Canada, Ontario
Toronto General Hospital
Toronto, Ontario, Canada, M5G 2C4
Sponsors and Collaborators
New England Research Institutes
National Heart, Lung, and Blood Institute (NHLBI)
Thalassemia Clinical Research Network
Investigators
Principal Investigator: Alan R. Cohen, MD Children's Hospital of Philadelphia
Principal Investigator: Patricia J. Giardina, MD Weill Medical College of Cornell University
Principal Investigator: Ellis J. Neufeld, MD, PhD Children's Hospital Medical Center, Cincinnati
Principal Investigator: Nancy F. Olivieri, MD Toronto General Hospital
Principal Investigator: Elliott P. Vichinsky, MD Children's Hospital & Research Center Oakland
Principal Investigator: Sonja McKinlay, PhD New England Research Institutes, Inc.
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00000623     History of Changes
Other Study ID Numbers: 317  U01HL065232  U01HL065233  U01HL065238  U01HL065239  U01HL065244  U01HL065260 
Study First Received: October 27, 1999
Last Updated: March 3, 2014
Health Authority: United States: Federal Government

Keywords provided by New England Research Institutes:
chelator
iron
transfusion
anemia
thalassemia

Additional relevant MeSH terms:
Thalassemia
Beta-Thalassemia
Anemia
Osteoporosis
Iron Overload
Hematologic Diseases
Hypertension, Pulmonary
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hemoglobinopathies
Genetic Diseases, Inborn
Iron Metabolism Disorders
Metabolic Diseases
Lung Diseases
Respiratory Tract Diseases
Sildenafil Citrate
Decitabine
Deferiprone
Deferoxamine
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents
Antimetabolites, Antineoplastic
Antimetabolites

ClinicalTrials.gov processed this record on September 23, 2016